Mizutani S, Mizutani E
Daiya Building Ladys' Clinic, Meieki, Nakamura-ku, Nagoya, Japan.
Exp Clin Endocrinol Diabetes. 2015 Mar;123(3):159-64. doi: 10.1055/s-0034-1398622. Epub 2015 Feb 6.
Fetal peptide hormones are essential for the development of fetus, which increase in accordance with pregnancy term. Concentration of these hormones within the feto-placental unit is normally higher than that of maternal circulation. Since these hormones are biologically active, the leakage of these hormones into the maternal circulation is regulated by degradation activity by placental aminopeptidases, in order to maintain the balance between carriage of pregnancy and onset of labor.Because the concentration of these hormones, being regulated by the amount of endogenous production and by physiological degradation by enzymes in the blood and tissue, the balance between production and degradation is a definitive element for maintaining normal gestation and term delivery.The changes of the balance between fetal angiotensin II (A-II) and vasopressin (AVP) andA-II and AVP degrading enzymes, between aminopeptidase A (APA) and placental leucine aminopeptidase( P-LAP) - in the placenta and maternal blood due to fetal stress such as hypoxia - are the provable causes of preeclampsia or preterm labor.Induction of APA and P-LAP by estradiol benzoate (E2) and progesterone (P) from placenta has been demonstrated. They are involved in the regulation of fetal peptide hormones via placental aminopeptidases in homeostasis of pregnancy.Recently it was shown that both APA and P-LAP could be potentially safe and effective drugs for preeclampsia and preterm labor. The authors' proposed sex steroid treatment with dose increasing manner by gestational week (sex steroid treatment) for severe preeclampsia and preterm labor could be candidates replacing conventional treatments. In light of lacking safe and effective medication, the proposed sex steroid treatment is worthwhile for the prospective controlled studies for the treatment of both preeclampsia and preterm labor.
胎儿肽类激素对胎儿发育至关重要,其会随着孕周增加。这些激素在胎儿 - 胎盘单位内的浓度通常高于母体循环中的浓度。由于这些激素具有生物活性,为维持妊娠进程与分娩发动之间的平衡,胎盘氨肽酶的降解活性会调节这些激素向母体循环中的渗漏。因为这些激素的浓度受内源性产生量以及血液和组织中酶的生理降解作用调节,所以产生与降解之间的平衡是维持正常妊娠和足月分娩的决定性因素。胎儿应激(如缺氧)导致胎盘中以及母体血液中胎儿血管紧张素II(A-II)与血管加压素(AVP)以及A-II与AVP降解酶之间,氨肽酶A(APA)与胎盘亮氨酸氨肽酶(P-LAP)之间平衡的变化,是子痫前期或早产的可证实原因。已证实胎盘分泌的苯甲酸雌二醇(E2)和孕酮(P)可诱导APA和P-LAP。它们通过胎盘氨肽酶参与妊娠稳态中胎儿肽类激素的调节。最近研究表明,APA和P-LAP都可能是治疗子痫前期和早产的安全有效药物。作者提出的按孕周递增剂量的性类固醇治疗(性类固醇治疗)用于重度子痫前期和早产,可能是替代传统治疗的候选方法。鉴于缺乏安全有效的药物,所提出的性类固醇治疗值得用于子痫前期和早产治疗的前瞻性对照研究。